<p>/PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM)（“PAVmed” 或 “公司”）是一家多元化的商业阶段医疗技术公司，业务涵盖医疗设备、诊断和数字健康领域，今天宣布将进行 1 比 30 的反向股票拆分（“普通股”）。反向股票拆分将于 2026 年 1 月 2 日东部时间凌晨 12:01 生效。公司的普通股将继续在纳斯达克资本市场（“纳斯达克”）以 “PAVM” 符号交易，并将在 2026 年 1 月 2 日市场开盘时以拆分调整后的基础开始交易。反向股票拆分旨在使公司符合纳斯达克上市的 1.00 美元最低出价要求。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2011714/PAVmed_updated_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2011714/PAVmed_updated_Logo.jpg"/></p>
<p>反向股票拆分已获得公司股东在 2025 年 12 月 5 日召开的特别股东会议上的批准，具体比例将由公司董事会在批准的参数内自行决定。1 比 30 的比例于 2025 年 12 月 8 日获得董事会批准。在反向股票拆分生效时，普通股的授权股份将从 250,000,000 减少至 25,000,000（该减少已在同一特别会议上获得公司股东的批准，前提是完成反向股票拆分）。</p>
<p>由于反向股票拆分，普通股的可发行股份数量将在公司股权激励计划和员工股票购买计划中按比例减少。此外，公司的未到期股票期权的行使价格和股份数量，以及公司的可转换证券（包括可转换债务和优先股）的转换价格也将按其各自条款按比例调整。</p>
<p>在反向股票拆分中不会发行任何普通股的零碎股份。因反向股票拆分而持有零碎股份的股东，其零碎股份将向上舍入至最接近的整股普通股。</p>
<p>反向股票拆分后普通股的新 CUSIP 号码为 70387R 502。</p>
<p><strong>关于 PAVmed 及其子公司</strong></p>
<p>PAVmed Inc.是一家多元化的商业阶段医疗技术公司，业务涵盖医疗设备、诊断和数字健康领域。其子公司 Lucid Diagnostics Inc.（NASDAQ: LUCD）是一家商业阶段的癌症预防医疗诊断公司，市场上销售 EsoGuard®食管 DNA 检测和 EsoCheck®食管细胞采集装置——这是用于广泛早期检测食管癌前期的首个也是唯一的商业工具，以降低食管癌死亡的风险。其另一子公司 Veris Health Inc.是一家数字健康公司，专注于通过使用具有无线通信的可植入生物传感器进行远程患者监测，提供增强的个性化癌症护理，并配备一套定制的连接外部设备。Veris 正在同时开发一种可植入的生理监测仪，设计为与化疗端口一起植入，将与 Veris 癌症护理平台接口。</p>
<p>欲了解更多信息，请访问 pavmed.com。</p>
<p>欲了解 Lucid Diagnostics 的更多信息，请访问 luciddx.com。</p>
<p>欲了解 Veris Health 的更多信息，请访问 verishealth.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含涉及风险和不确定性的前瞻性声明。前瞻性声明是指任何非历史事实的声明。这些前瞻性声明基于 PAVmed 和 Lucid 管理层当前的信念和期望，可能面临风险和不确定性，这可能导致实际结果与前瞻性声明有所不同。可能导致这些差异的风险和不确定性包括但不限于 PAVmed 和 Lucid 普通股价格的波动；一般经济和市场条件；研究和开发中固有的不确定性，包括推进 PAVmed 和 Lucid 产品至监管提交所需的成本和时间；监管机构是否对 PAVmed 和 Lucid 的临床和前临床研究的设计和结果感到满意；PAVmed 和 Lucid 的产品是否以及何时获得监管机构的批准；PAVmed 和 Lucid 的产品在获得批准和商业化后的市场接受度；PAVmed 和 Lucid 是否能够根据需要筹集额外资金；以及其他竞争性发展。此外，新的风险和不确定性可能会不时出现，且难以预测。有关可能影响 PAVmed 和 Lucid 未来运营的这些及其他重要风险和不确定性的进一步列表和描述，请参见 PAVmed 和 Lucid 最近提交给证券交易委员会的 10-K 表格年度报告中的第一部分，项目 1A，“风险因素”，以及在 PAVmed 或 Lucid 最近的年度报告后提交的任何 10-Q 季度报告中的第二部分，项目 1A，“风险因素”。PAVmed 和 Lucid 不承担公开更新或修订任何前瞻性声明的意图或义务，以反映其期望或基于这些期望的事件、条件或情况的变化，或可能影响实际结果与前瞻性声明中所包含的结果之间差异的可能性。</p>
<p>来源：PAVmed Inc.</p>

PAVM

<p>PAVmed Inc. 宣布将于 2026 年 1 月 2 日实施 1 股换 30 股的反向股票拆分，以符合纳斯达克 1.00 美元的最低竞标价格要求。该拆分已获得股东批准，将把授权股份从 2.5 亿股减少至 2500 万股。股权激励计划下的股份数量和未行使的股票期权将按比例调整。不会发行零碎股份；它们将被四舍五入到最接近的整股。普通股的新 CUSIP 号码将为 70387R 502</p>

<p>, /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) (&#34;PAVmed&#34; or the &#34;Company&#34;), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced it will conduct a 1-for-30 reverse stock split of its common stock (the &#34;Common Stock&#34;). The reverse stock split will become effective on January 2, 2026, at 12:01 a.m. Eastern Time. The Company's Common Stock will continue to trade on the Nasdaq Capital Market (&#34;Nasdaq&#34;) under the symbol &#34;PAVM&#34; and will begin trading on a split-adjusted basis at the opening of the market on January 2, 2026. The reverse stock split is intended to bring the Company into compliance with the $1.00 minimum bid price requirement for maintaining the listing of its Common Stock on Nasdaq.</p>
<div class="lb-trans"><p>/PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM)（“PAVmed” 或 “公司”）是一家多元化的商业阶段医疗技术公司，业务涵盖医疗设备、诊断和数字健康领域，今天宣布将进行 1 比 30 的反向股票拆分（“普通股”）。反向股票拆分将于 2026 年 1 月 2 日东部时间凌晨 12:01 生效。公司的普通股将继续在纳斯达克资本市场（“纳斯达克”）以 “PAVM” 符号交易，并将在 2026 年 1 月 2 日市场开盘时以拆分调整后的基础开始交易。反向股票拆分旨在使公司符合纳斯达克上市的 1.00 美元最低出价要求。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2011714/PAVmed_updated_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/2011714/PAVmed_updated_Logo.jpg"/></p>
<p>The reverse stock split was approved by the Company's stockholders at the Company's special meeting of stockholders held on December 5, 2025, with the specific ratio to be determined at the discretion of the Company's board of directors within approved parameters. The ratio of 1-for-30 was approved by the board on December 8, 2025. As of the effective time of the reverse stock split, the authorized shares of Common Stock will be reduced from 250,000,000 to 25,000,000 (which reduction was approved, subject to completion of the reverse stock split, by the Company's stockholders at the same special meeting).</p>
<div class="lb-trans"><p>反向股票拆分已获得公司股东在 2025 年 12 月 5 日召开的特别股东会议上的批准，具体比例将由公司董事会在批准的参数内自行决定。1 比 30 的比例于 2025 年 12 月 8 日获得董事会批准。在反向股票拆分生效时，普通股的授权股份将从 250,000,000 减少至 25,000,000（该减少已在同一特别会议上获得公司股东的批准，前提是完成反向股票拆分）。</p>
</div><p>As a result of the reverse stock split, the number of shares of Common Stock available for issuance under the Company's equity incentive plan and employee stock purchase plan immediately prior to the reverse stock split will be proportionately reduced. In addition, the exercise prices of and number of shares subject to the Company's outstanding stock options, and the conversion prices of the Company's outstanding convertible securities, including its convertible debt and preferred stock, will likewise be proportionately adjusted in accordance with their respective terms.</p>
<div class="lb-trans"><p>由于反向股票拆分，普通股的可发行股份数量将在公司股权激励计划和员工股票购买计划中按比例减少。此外，公司的未到期股票期权的行使价格和股份数量，以及公司的可转换证券（包括可转换债务和优先股）的转换价格也将按其各自条款按比例调整。</p>
</div><p>No fractional shares of Common Stock will be issued in connection with the reverse stock split. Stockholders that would hold a fractional share of Common Stock as a result of the reverse stock split will have such fractional shares of Common Stock rounded up to the nearest whole share of Common Stock.</p>
<div class="lb-trans"><p>在反向股票拆分中不会发行任何普通股的零碎股份。因反向股票拆分而持有零碎股份的股东，其零碎股份将向上舍入至最接近的整股普通股。</p>
</div><p>The new CUSIP number for the Common Stock following the reverse stock split is 70387R 502.</p>
<div class="lb-trans"><p>反向股票拆分后普通股的新 CUSIP 号码为 70387R 502。</p>
</div><p><strong>About PAVmed and its Subsidiaries</strong></p>
<div class="lb-trans"><p><strong>关于 PAVmed 及其子公司</strong></p>
</div><p>PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.</p>
<div class="lb-trans"><p>PAVmed Inc.是一家多元化的商业阶段医疗技术公司，业务涵盖医疗设备、诊断和数字健康领域。其子公司 Lucid Diagnostics Inc.（NASDAQ: LUCD）是一家商业阶段的癌症预防医疗诊断公司，市场上销售 EsoGuard®食管 DNA 检测和 EsoCheck®食管细胞采集装置——这是用于广泛早期检测食管癌前期的首个也是唯一的商业工具，以降低食管癌死亡的风险。其另一子公司 Veris Health Inc.是一家数字健康公司，专注于通过使用具有无线通信的可植入生物传感器进行远程患者监测，提供增强的个性化癌症护理，并配备一套定制的连接外部设备。Veris 正在同时开发一种可植入的生理监测仪，设计为与化疗端口一起植入，将与 Veris 癌症护理平台接口。</p>
</div><p>For more and for more information about PAVmed, please visit pavmed.com.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 pavmed.com。</p>
</div><p>For more information about Lucid Diagnostics, please visit luciddx.com.</p>
<div class="lb-trans"><p>欲了解 Lucid Diagnostics 的更多信息，请访问 luciddx.com。</p>
</div><p>For more information about Veris Health, please visit verishealth.com.</p>
<div class="lb-trans"><p>欲了解 Veris Health 的更多信息，请访问 verishealth.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's and Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's and Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's and Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's and Lucid's clinical and preclinical studies; whether and when PAVmed's and Lucid's products are cleared by regulatory authorities; market acceptance of PAVmed's and Lucid's products once cleared and commercialized; PAVmed's and Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's and Lucid's future operations, see Part I, Item 1A, &#34;Risk Factors,&#34; in PAVmed's and Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, &#34;Risk Factors&#34; in any Quarterly Report on Form 10-Q filed by PAVmed or Lucid after its most recent Annual Report. PAVmed and Lucid disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.</p>
<div class="lb-trans"><p>本新闻稿包含涉及风险和不确定性的前瞻性声明。前瞻性声明是指任何非历史事实的声明。这些前瞻性声明基于 PAVmed 和 Lucid 管理层当前的信念和期望，可能面临风险和不确定性，这可能导致实际结果与前瞻性声明有所不同。可能导致这些差异的风险和不确定性包括但不限于 PAVmed 和 Lucid 普通股价格的波动；一般经济和市场条件；研究和开发中固有的不确定性，包括推进 PAVmed 和 Lucid 产品至监管提交所需的成本和时间；监管机构是否对 PAVmed 和 Lucid 的临床和前临床研究的设计和结果感到满意；PAVmed 和 Lucid 的产品是否以及何时获得监管机构的批准；PAVmed 和 Lucid 的产品在获得批准和商业化后的市场接受度；PAVmed 和 Lucid 是否能够根据需要筹集额外资金；以及其他竞争性发展。此外，新的风险和不确定性可能会不时出现，且难以预测。有关可能影响 PAVmed 和 Lucid 未来运营的这些及其他重要风险和不确定性的进一步列表和描述，请参见 PAVmed 和 Lucid 最近提交给证券交易委员会的 10-K 表格年度报告中的第一部分，项目 1A，“风险因素”，以及在 PAVmed 或 Lucid 最近的年度报告后提交的任何 10-Q 季度报告中的第二部分，项目 1A，“风险因素”。PAVmed 和 Lucid 不承担公开更新或修订任何前瞻性声明的意图或义务，以反映其期望或基于这些期望的事件、条件或情况的变化，或可能影响实际结果与前瞻性声明中所包含的结果之间差异的可能性。</p>
</div><p>SOURCE PAVmed Inc.</p>
<div class="lb-trans"><p>来源：PAVmed Inc.</p>
</div>

PAVmed 宣布进行反向股票拆分 | LUCD 股票新闻